Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models

Medannex Ltd (Edinburgh) today announced new data for their first-in-class targeted agent, MDX-124, showing significant anti-tumour activity in preclinical pancreatic cancer models. The results were released at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium in San Francisco, USA.

MDX-124 induces cell cycle arrest, preventing cancer cells progressing from the growth phase (G1) to the DNA synthesis phase (S). This causes a significant reduction in cancer cell proliferation and greatly increases primary tumour necrosis. Furthermore, MDX-124 significantly decreases cancer cell migration, and reduces both the incidence and burden of metastatic spread – the major cause of cancer mortality.

In December, Medannex released data showing MDX-124 has potent activity in breast cancer models and significant synergy when combined with widely used chemotherapies cisplatin and paclitaxel. Today’s data demonstrate synergy between MDX-124 and two additional chemotherapies, 5-FU and gemcitabine, which are standard-of-care treatments for several cancers, including pancreatic.

Professor Daniel Palmer, of the University of Liverpool’s Department of Molecular and Clinical Cancer Medicine, commented: ‘Pancreatic cancer is incredibly challenging and we desperately need new therapies. These non-clinical data suggest that MDX-124 could provide a new treatment option as a single agent or in combination with established cancer therapies and clinical trials are now eagerly anticipated.’

Medannex CEO Ian Abercrombie said: ‘We are very encouraged by these data, especially the impressive added benefit when combining MDX-124 with established cancer drugs. This demonstrates great potential for our agent to improve outcomes for patients. We look forward to exploring this further in our imminent First-in-Human study, which will include patients with pancreatic cancer.

The new data were generated by Medannex in collaboration with the University of Liverpool, ARU (Cambridge) and Brighton & Sussex Medical School, and can be viewed in full here


 

More news and updates

Coulter Partners places Chief Operating Officer at Treadwell Therapeutics, playing an integral role in the company’s evolution

Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health, and Tech, recently partnered with Treadwell Therapeutics, a clinical-stage biotechnology company developing novel, cross-modality medicines for unmet needs in cancer, and are pleased to announce the placement of J.D. Mowery as Chief Operating Officer (COO).

Innovation community at The Oxford Science Park expands further as companies move into the Hayakawa Building

The innovation community at The Oxford Science Park, one of Europe's leading locations for science and technology companies, continues to expand as firms move into the newly refurbished Hayakawa Building.

Coulter Partners announces two additional appointments in Italy

Coulter Partners announces two additional appointments to its new Milan office. Giulia Bacis joins as Senior Consultant and Anna Senzacqua as Consultant. Together with Francesca Lazzarin, Executive Director, Yasemin Holland, Senior Research Associate and Giuliana Milioto, Research Associate, they make up the Italian team who will enrich the firm’s offering to companies growing from Italian headquarters and those expanding into Italy.

BioIVT to Provide Rare Biosamples for the FNIH Biomarkers Consortium Neurodegenerative Disease Project

BioIVT is sourcing matched sets of cerebrospinal fluid, serum, and plasma from donors afflicted with ALS to further research of neurofilament in the blood as a biomarker for early stages of neurodegeneration.

More within